Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban

Abstract

The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.

1 . A method of treating pulmonary arterial hypertension in a human in need of treatment thereof, comprising administering a therapeutically effective amount of a [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (ifetroban) or a pharmaceutically acceptable salt thereof to the mammal human. 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . The method of  claim 1  wherein the therapeutically effective amount is from 10 mg to 1000 mg per day. 
     
     
         8 . The method of  claim 7 , wherein the ifetroban or the pharmaceutically acceptable salt thereof is administered orally, intranasally, rectally, vaginally, sublingually, buccally, parenterally, or transdermally. 
     
     
         9 - 19 . (canceled) 
     
     
         20 . The method of  claim 1 , wherein the pharmaceutically acceptable salt of ifetroban is ifetroban sodium. 
     
     
         21 . The method of  claim 7 , wherein the therapeutically effective amount is from 100 mg to 500 mg per day. 
     
     
         22 . The method of  claim 20 , wherein the ifetroban sodium is in an oral solid dosage form. 
     
     
         23 . The method of  claim 7 , wherein the therapeutically effective amount is 250 mg per day. 
     
     
         24 . The method of  claim 8 , wherein the ifetroban or the pharmaceutically acceptable salt thereof is administered orally. 
     
     
         25 . The method of  claim 22 , wherein the therapeutically effective amount is 250 mg per day. 
     
     
         26 . The method of  claim 1 , wherein the pulmonary arterial hypertension is associated with systemic sclerosis.